Search results for "immunologic factor"

showing 10 items of 128 documents

Rituximab in AChR subtype of myasthenia gravis: systematic review

2020

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterised by an autoantibody against acetylcholine receptor (AChR-Ab), autoantibody against muscle-specific kinase (MuSK-Ab), lipoprotein-related protein 4 or agrin in the postsynaptic membrane at the neuromuscular junction. Many patients are resistant to conventional treatment and effective therapies are needed. Rituximab (RTX) is a monoclonal antibody directed against CD20 antigen on B cells which has been successfully employed in anti-MuSK-Ab+MG, but the efficacy in anti-AChR-Ab+MG is still debated. The purpose of this systematic review was to describe the best evidence for RTX in the acetylcholine …

Oncologymedicine.medical_specialtyneuroimmunologyNeuromuscular junctionimmunology03 medical and health sciences0302 clinical medicineInternal medicineMyasthenia GravismedicineHumansImmunologic FactorsReceptors Cholinergic030304 developmental biologyAcetylcholine receptorCD200303 health sciencesAgrinbiologyimmunology; myasthenia; neuroimmunology; neuromuscularbusiness.industryAutoantibodyReceptor Protein-Tyrosine Kinasesmedicine.diseaseMyasthenia gravismyastheniaDiscontinuationPsychiatry and Mental healthTreatment Outcomemedicine.anatomical_structurebiology.proteinSettore MED/26 - NeurologiaSurgeryRituximabneuromuscularNeurology (clinical)Rituximabbusiness030217 neurology & neurosurgerymedicine.drugJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Isolation and Characterization of CD276+/HLA-E+ Human Subendocardial Mesenchymal Stem Cells from Chronic Heart Failure Patients: Analysis of Differen…

2012

Mesenchymal stem cells (MSCs) are virtually present in all postnatal organs as well as in perinatal tissues. MSCs can be differentiated toward several mature cytotypes and interestingly hold potentially relevant immunomodulatory features. Myocardial infarction results in severe tissue damage, cardiomyocyte loss, and eventually heart failure. Cellular cardiomyoplasty represents a promising approach for myocardial repair. Clinical trials using MSCs are underway for a number of heart diseases, even if their outcomes are hampered by low long-term improvements and the possible presence of complications related to cellular therapy administration. Therefore, elucidating the presence and role of MS…

Pathologymedicine.medical_specialtyB7 AntigensHeart VentriclesGene ExpressionCell SeparationBiologyCell therapyHLA-EAntigens CDOsteogenesisCellular cardiomyoplastymedicineHumansImmunologic FactorsMyocardial infarctionCells CulturedHeart FailureAdipogenesisMesenchymal stem cells human heart stromal progenitors post-infarct chronic heart failure cardiomyocyte markers immune modulation inflammation cardiac remodelling regenerative medicineSettore BIO/16 - Anatomia UmanaHistocompatibility Antigens Class IMesenchymal stem cellMesenchymal Stem CellsCell BiologyHematologyAnatomymedicine.diseaseClinical trialmedicine.anatomical_structureVentricleHeart failureChondrogenesisBiomarkersDevelopmental BiologyStem Cells and Development
researchProduct

Immunomodulation in vascularized composite allotransplantation: What is the role for adipose-derived stem cells?

2019

Hand and face transplants are becoming increasingly common, recording progressively more penile, uterus, abdominal wall, and allotransplantation cases reported worldwide. Despite current protocols allow long-term survival of the allografts, the ultimate goal of donor-specific tolerance has not been achieved yet. In fact, the harmful adverse effects related to the lifelong administration of immunosuppressive agents are the main drawbacks for vascularized composite allotransplantations. Research is very active in investigating alternative methods to induce greater tolerance while minimizing toxicity. Adipose-derived stem cells (ASCs) represent promising cell therapies for immunomodulation in …

Pathologymedicine.medical_specialtymedicine.medical_treatmentUterusAdipose tissue030230 surgeryVascularized Composite AllotransplantationAbdominal wall03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansImmunologic Factorscell-based therapieadipose-derived stem cellbusiness.industryGraft Survivalface transplantationvascularized composite allotransplantationmedicine.anatomical_structureAdipose Tissue030220 oncology & carcinogenesisTransplantation ToleranceSurgerybusinessHand transplantationAllotransplantationhand transplantation
researchProduct

Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis: two case reports

2017

Abstract Background Anti-N-methyl-D-aspartate receptor encephalitis is a rare autoimmune disease characterized by severe neurological and psychiatric symptoms and a difficult diagnosis. The disease is often secondary to a neoplastic lesion, seldom diagnosed years later. Psychiatric symptoms are prevalent in adults; neurologic symptoms are more evident in children, who typically present primarily with neurological symptoms. To the best of our knowledge, the association with juvenile idiopathic arthritis has not been described. Case presentation We report the cases of two caucasian girls with an atypical presentation. The first patient was an 8-year-old girl with normal psychomotor developmen…

PediatricsPathologyChoreiform movementAnti-Inflammatory AgentsArthritislcsh:MedicineCase ReportDisease0302 clinical medicinePrednisoneChildOvarian Neoplasms030219 obstetrics & reproductive medicineMedicine (all)Remission InductionTeratomaImmunoglobulins IntravenousGeneral MedicineMagnetic Resonance ImagingTreatment OutcomeMethylprednisoloneFemaleHip JointTeratomamedicine.symptomEncephalitismedicine.drugmedicine.medical_specialtyAdolescentAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Medicine (all)Methylprednisolone03 medical and health sciencesJuvenile idiopathic arthritiChoreaPsychiatric symptomsmedicineHumansImmunologic FactorsAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; TeratomaAnti-N-methyl-D-aspartate receptor encephalitis; Chorea; Juvenile idiopathic arthritis; Psychiatric symptoms; Speech disorders; Teratoma; Adolescent; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Arthritis Infectious; Child; Female; Hip Joint; Humans; Immunoglobulins Intravenous; Immunologic Factors; Magnetic Resonance Imaging; Methylprednisolone; Ovarian Neoplasms; Remission Induction; Teratoma; Treatment Outcome; Medicine (all)Speech disorderSpeech disordersArthritis InfectiousPsychiatric symptombusiness.industrylcsh:RChoreaJuvenile idiopathic arthritismedicine.diseaseAnti-N-methyl-D-aspartate receptor encephalitisbusiness030217 neurology & neurosurgeryAnti-N-methyl-D-aspartate receptor encephaliti
researchProduct

Immunomodulating role of bisphosphonates on human gamma delta T cells: an intriguing and promising aspect of their antitumour activity.

2007

Vgamma9Vdelta2 T cells have the ability to produce inflammatory cytokines involved in protective immunity against intracellular pathogens and tumours and to display strong cytolytic as well as bactericidal activities. This suggests a direct involvement of Vgamma9Vdelta2 T lymphocytes in immune control of cancer and infections. These observations have recently aided development of novel immunotherapeutic approaches aimed at Vgamma9Vdelta2 T cell activation. Nitrogen-containing bisphosphonates (N-BPs) play a crucial role in Vgamma9Vdelta2 T lymphocyte activation and in the acquisition of effector functions. The preliminary results of these innovative strategies are encouraging. Moreover, comp…

Protective immunitymedicine.medical_treatmentT cellT-Lymphocytesantitumour bisphophonate human gamma delta T cells immunomodulatory immunotherapyClinical BiochemistryAntineoplastic AgentsBiologyMonocytesProinflammatory cytokineT-Lymphocyte SubsetsNeoplasmsDrug DiscoverymedicineAnimalsHumansImmunologic FactorsPharmacologyDiphosphonatesMechanism (biology)Intracellular parasiteCancerImmunotherapyDendritic Cellsmedicine.diseaseCytolysismedicine.anatomical_structureImmunologyMolecular MedicineInterleukin-2Bone DiseasesExpert opinion on therapeutic targets
researchProduct

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement

2019

Rationale: Immune checkpoint inhibitors (ICIs) have revolutionized cancer care but are associated with unique adverse events, including potentially life-threatening pneumonitis. The diagnosis of ICI-pneumonitis is increasing; however, the biological mechanisms, clinical and radiologic features, and the diagnosis and management have not been well defined. Objectives: To summarize evidence, identify knowledge and research gaps, and prioritize topics and propose methods for future research on ICI-pneumonitis. Methods: A multidisciplinary group of international clinical researchers reviewed available data on ICI-pneumonitis to develop and refine research questions pertaining to ICI-pneumonitis.…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyBiomedical ResearchLung Neoplasmsmedicine.medical_treatmentMEDLINENSCLCCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineRisk FactorsCarcinoma Non-Small-Cell LungInternal medicinepolycyclic compoundsmedicineCarcinomaHumansImmunologic FactorsOrganizational Objectives030212 general & internal medicineAdverse effectLung cancerSocieties MedicalPneumonitisAmerican Thoracic Society Documentsinterstitial lung diseasebusiness.industryInterstitial lung diseaseCancerPneumoniaImmunotherapymedicine.diseaseUnited StatesGenes cdclung cancer030228 respiratory systemResearch Designimmunotherapybusinesshormones hormone substitutes and hormone antagonistsAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

IqYmune® is an effective maintenance treatment for multifocal motor neuropathy: A randomised, double‐blind, multi‐center cross‐over non‐inferiority s…

2018

Intravenous immunoglobulin (IVIg) is the gold-standard for maintenance treatment of multifocal motor neuropathy (MMN). This phase III, randomised, double-blind, multi-centre, active-control, crossover study, aimed to evaluate the non-inferiority of IqYmune® relative to Kiovig®, primarily based on efficacy criteria. Twenty-two adult MMN patients, treated with any brand of IVIg (except Kiovig® or IqYmune®) at a stable maintenance dose within the range of 1 to 2 g/kg every 4 to 8 weeks, were randomised to receive either Kiovig® followed by IqYmune®, or IqYmune® followed by Kiovig®. Each product was administered for 24 weeks. The primary endpoint was the difference between IqYmune® and Kiovig® …

Research ReportIVIgAdultMalemedicine.medical_specialtymultifocal motor neuropathyEquivalence Trials as Topiclaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawInternal medicineOutcome Assessment Health CaremedicineClinical endpointHumansImmunologic FactorsMotor Neuron DiseaseAgedCross-Over StudiesMaintenance dosebusiness.industryGeneral NeuroscienceImmunoglobulins IntravenousResearch Reportsclinical trialMiddle AgedHaemolysismedicine.diseaseCrossover studyConfidence intervalTolerability030220 oncology & carcinogenesisFemaleNeurology (clinical)businessimmunoglobulin030217 neurology & neurosurgeryMultifocal motor neuropathyJournal of the Peripheral Nervous System
researchProduct

Wheat Amylase Trypsin Inhibitors as Nutritional Activators of Innate Immunity

2015

While the central role of an adaptive, T cell-mediated immune response to certain gluten peptides in celiac disease is well established, the innate immune response to wheat proteins remains less well defined. We identified wheat amylase trypsin inhibitors (ATIs), but not gluten, as major stimulators of innate immune cells (dendritic cells > macrophages > monocytes), while intestinal epithelial cells were nonresponsive. ATIs bind to and activate the CD14-MD2 toll-like receptor 4 (TLR4) complex. This activation occurs both in vitro and in vivo after oral ingestion of purified ATIs or gluten, which is usually enriched in ATIs. Wheat ATIs represent a family of up to 17 proteins with molec…

T cellBiologyMicrobiologyImmune systemImmunitymedicineAnimalsHumansImmunologic FactorsNutritional Physiological PhenomenaTriticumchemistry.chemical_classificationInnate immune systemMonocyteGastroenterologynutritional and metabolic diseasesGeneral MedicineDendritic cellAcquired immune systemGlutenImmunity Innatemedicine.anatomical_structurechemistryBiochemistryAmylasesTrypsin InhibitorsDigestive Diseases
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

Prostaglandin E(2)-loaded microspheres as strategy to inhibit phagocytosis and modulate inflammatory mediators release.

2008

PGE(2), an arachidonic acid metabolite produced by various type of cells regulates a broad range of physiological activities in the endocrine, cardiovascular, gastrointestinal, and immune systems, and is involved in maintaining the local homeostasis. In the immune system, PGE(2) is mainly produced by APCs and it can suppress the Th1-mediated immune responses. The aim of this study was to develop PGE(2)-loaded biodegradable MS that prolong and sustain the in vivo release of this mediator. An o/w emulsion solvent extraction-evaporation method was chosen to prepare the MS. We determined their diameters, evaluated the in vitro release of PGE(2), using enzyme immunoassay and MS uptake by periton…

Time Factorsmedicine.medical_treatmentPhagocytosisChemistry PharmaceuticalDrug CompoundingPharmaceutical ScienceInflammationPharmacologyBiologyNitric OxideDinoprostonechemistry.chemical_compoundMiceImmune systemPhagocytosisIn vivoSepsismedicineAnimalsHumansImmunologic FactorsProstaglandin E2Particle SizeCells CulturedChemokine CCL2Tumor Necrosis Factor-alphaEndothelial CellsWaterGeneral MedicineMicrospheresDisease Models AnimalchemistryBiochemistrySolubilityDelayed-Action PreparationsMacrophages PeritonealLiberationlipids (amino acids peptides and proteins)Arachidonic acidEmulsionsmedicine.symptomInflammation MediatorsOilsBiotechnologyProstaglandin Emedicine.drugEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct